VIVE stock rose in early trading on December 31, 2019, after the company regained compliance with the Nasdaq.

Viveve Medical announced that it has been notified by Nasdaq that Viveve has regained compliance with the Nasdaq Capital Market continued listing requirements, the scheduled hearing before the Nasdaq Hearings Panel has been cancelled, and Viveve will continue to trade on the Nasdaq Capital Market.

On December 18, 2019, Viveve announced that it has received approval of its investigational testing application, or ITA, from the Canadian Ministry of Health to conduct a three-arm, three-month feasibility study to compare Viveve’s cryogen-cooled monopolar radiofrequency, or CMRF, treatment and a cryogen-only sham to an inert sham treatment for the improvement of stress urinary incontinence, or SUI, in women. Pending Investigational Review Board approvals of the ITA cleared SUI treatment protocol, the company anticipates rapid study initiation and subject enrollment with a potential data readout in Q2 of 2020. If the results show a definitive difference between the study arms, the company intends to resubmit its pending investigational device exemption application to the FDA for approval to conduct the LIBERATE-U.S. trial for improvement of mild to moderate SUI in women.

On December 17, 2019, GreenSky Patient Solutions, LLC, a leading financial technology company Powering Commerce at the Point of Sale®, today announced it has signed a strategic sponsorship agreement with Viveve Medical, Inc (NASDAQ: VIVE) to enable Viveve physician customers to offer customized financing solutions so their patients can receive the non‐surgical solutions they seek.

Viveve is a medical technology company committed to advancing new solutions to improve women’s overall well‐being and quality of life. As more women request non‐surgical solutions to meet their health needs, Viveve uses safe and effective technologies specifically designed for women’s intimate health. Viveve provides clinically proven, innovative, non‐surgical treatments to improve women’s intimate health conditions.

The internationally patented Viveve® System incorporates cryogen‐cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in‐office session. Viveve Solutions address the unmet needs for safe and effective non‐invasive treatments for vaginal laxity, stress urinary incontinence (SUI), and improved pelvic floor strength conditions experienced by women.

“Today we believe the Viveve treatment, represents the most clinically studied, safe and effective non‐invasive procedure to address vaginal laxity and improve sexual function. This is evidenced by international regulatory approvals and clearances for these indications in over 50 countries,” said Scott Durbin, Viveve’s chief executive officer and director.

“We’re pleased to partner with Viveve so more healthcare providers can offer their patients expanded options for purchasing these treatments to improve their overall well‐being,” said Dennis Kelly, president of GreenSky Patient Solutions®.

This strategic sponsorship enables Viveve’s network of providers the opportunity to offer flexible financing solutions, including revolving credit and installment loan products, so their patients can receive the care they seek.

On December 3, 2019, Ladenburg upgraded Viveve to Buy from Neutral.

finviz dynamic chart for  vive
Women’s Health News From Google